Hall J, et al. - In this phase I, randomized, single-blind, placebo-controlled study including healthy Japanese and non-Asian adult male subjects, researchers evaluated verinurad pharmacokinetics, pharmacodynamics, and tolerability. They assayed serial plasma/serum and urine samples for verinurad and uric acid, and assessed safety by adverse events and laboratory data. Both healthy Japanese and non-Asian males exhibited a lowering of serum urate with verinurad monotherapy. It was well tolerated while exhibiting slight differences in plasma pharmacokinetics in the two groups.